DMAC
Income statement / Annual
Last year (2025), DiaMedica Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, DiaMedica Therapeutics Inc's net income was -$32.77 M.
See DiaMedica Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$500.00 K |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.00 K
|
$2.21 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$500.00 K
|
-$4.00 K
|
-$2.21 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
| Research and Development Expenses |
$24.61 M
|
$19.06 M
|
$13.11 M
|
$7.84 M
|
$8.77 M
|
$8.21 M
|
$7.90 M
|
$4.52 M
|
$3.21 M
|
$1.76 M
|
| General & Administrative Expenses |
$9.78 M
|
$7.43 M
|
$7.96 M
|
$6.06 M
|
$4.88 M
|
$4.49 M
|
$3.69 M
|
$2.74 M
|
$1.31 M
|
$718.05 K
|
| Selling & Marketing Expenses |
$0.00
|
$193.00 K
|
$196.00 K
|
$103.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.78 M
|
$7.62 M
|
$8.16 M
|
$6.16 M
|
$4.88 M
|
$4.49 M
|
$3.69 M
|
$2.74 M
|
$1.31 M
|
$718.05 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$68.00 K
|
$6.00 K
|
$0.00
|
| Operating Expenses |
$34.40 M
|
$26.68 M
|
$21.27 M
|
$14.00 M
|
$13.65 M
|
$12.70 M
|
$11.59 M
|
$6.05 M
|
$4.28 M
|
$2.48 M
|
| Cost And Expenses |
$34.40 M
|
$26.68 M
|
$21.27 M
|
$14.00 M
|
$13.65 M
|
$12.70 M
|
$11.59 M
|
$6.05 M
|
$4.28 M
|
$2.48 M
|
| Interest Income |
$0.00
|
$2.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.73 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$48.38 K
|
| Depreciation & Amortization |
$43.00 K
|
$39.00 K
|
$30.00 K
|
$25.00 K
|
$24.00 K
|
$21.00 K
|
$21.00 K
|
$15.00 K
|
$4.00 K
|
$2.21 K
|
| EBITDA |
-$34.35 M |
-$26.64 M |
-$21.24 M |
-$13.98 M |
-$13.62 M |
-$12.68 M |
-$11.57 M |
-$5.64 M |
-$4.26 M |
-$2.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-11.28
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-13.52
|
0
|
0
|
| Total Other Income/Expenses Net |
$1.66 M
|
$2.27 M
|
$1.93 M
|
$353.00 K
|
$82.00 K
|
$434.00 K
|
$975.00 K
|
$747.00 K
|
$259.00 K
|
$280.63 K
|
| Income Before Tax |
-$32.74 M
|
-$24.41 M
|
-$19.34 M
|
-$13.65 M
|
-$13.56 M
|
-$12.27 M
|
-$10.62 M
|
-$5.65 M
|
-$4.26 M
|
-$2.20 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-11.31
|
0
|
0
|
| Income Tax Expense |
$28.00 K
|
$30.00 K
|
$43.00 K
|
$28.00 K
|
$28.00 K
|
$27.00 K
|
$31.00 K
|
$80.00 K
|
-$9.00 K
|
$22.31 K
|
| Net Income |
-$32.77 M
|
-$24.44 M
|
-$19.38 M
|
-$13.68 M
|
-$13.59 M
|
-$12.29 M
|
-$10.65 M
|
-$5.73 M
|
-$4.26 M
|
-$2.22 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-11.47
|
0
|
0
|
| EPS |
-0.7 |
-0.6 |
-0.6 |
-0.52 |
-0.65 |
-0.78 |
-0.89 |
-0.74 |
-0.72 |
-0.47 |
| EPS Diluted |
-0.7 |
-0.6 |
-0.6 |
-0.52 |
-0.65 |
-0.78 |
-0.89 |
-0.74 |
-0.72 |
-0.47 |
| Weighted Average Shares Out |
$46.98 M
|
$40.40 M
|
$32.57 M
|
$26.44 M
|
$20.77 M
|
$15.68 M
|
$11.99 M
|
$7.74 M
|
$5.94 M
|
$4.74 M
|
| Weighted Average Shares Out Diluted |
$46.98 M
|
$40.40 M
|
$32.57 M
|
$26.44 M
|
$20.77 M
|
$15.68 M
|
$11.99 M
|
$7.74 M
|
$5.94 M
|
$4.74 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
